Literature DB >> 3595382

Is determination of serum N-terminal procollagen type III peptide (sPIIIP) a marker of hepatic fibrosis?

C Surrenti, A Casini, S Milani, S Ambu, P Ceccatelli, A D'Agata.   

Abstract

Serum N-terminal procollagen type III peptide (sPIIIP) levels were evaluated in 58 patients affected by chronic liver disease, in order to assess the usefulness of sPIIIP as a marker of hepatic fibrosis. In 45 patients sPIIIP was also correlated to liver histology; biopsies were scored by two of the authors, without knowledge of diagnosis. Compared to normal controls, sPIIIP concentration was found to be significantly elevated in chronic active hepatitis (CAH) and in cirrhosis, but not in fatty liver. Patients affected by chronic persistent hepatitis (CPH) had values of sPIIIP higher than normal in four of 11 cases considered. A close correlation was found between sPIIIP values and histological parameters of inflammation, necrosis, and degeneration, while the relationship between sPIIIP levels and fibrosis was weaker. These data suggest that sPIIIP determination may reflect the extent of inflammatory changes in the liver; but it cannot be considered a reliable index of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595382     DOI: 10.1007/bf01296135

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Collagen biosynthesis enzymes in serum and hepatic tissue in liver disease. II. Galactosylhydroxylysyl glucosyltransferase.

Authors:  E R Kuutti-Savolainen; H Anttinen; T A Miettinen; K I Kivirikko
Journal:  Eur J Clin Invest       Date:  1979-02       Impact factor: 4.686

2.  Collagen biosynthesis enzymes in serum and hepatic tissue in liver disease. I. Prolyl hydroxylase.

Authors:  E R Kuutti-Savolainen; J Risteli; T A Miettinen; K I Kivirikko
Journal:  Eur J Clin Invest       Date:  1979-02       Impact factor: 4.686

3.  Biochemical and immunochemical study of lysyl oxidase in experimental hepatic fibrosis in the rat.

Authors:  R C Siegel; K H Chen; J S Greenspan; J M Aguiar
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

Review 4.  Hepatic fibrosis. Correlation of biochemical and morphologic investigations.

Authors:  H Popper; S Uenfriend
Journal:  Am J Med       Date:  1970-11       Impact factor: 4.965

5.  A monoclonal antibody specific for the amino terminal cleavage site of procollagen type I.

Authors:  H G Foellmer; K Kawahara; J A Madri; H Furthmayr; R Timpl; L Tuderman
Journal:  Eur J Biochem       Date:  1983-07-15

6.  Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease.

Authors:  O Niemelä; L Risteli; E A Sotaniemi; J Risteli
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

7.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease.

Authors:  H Rohde; L Vargas; E Hahn; H Kalbfleisch; M Bruguera; R Timpl
Journal:  Eur J Clin Invest       Date:  1979-12       Impact factor: 4.686

8.  Morphometric investigations on the portal tracts of the liver, the differentiation of variable progression in chronic persistent hepatitis.

Authors:  J Volmer; C J Lüders
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

9.  The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease.

Authors:  A Frei; A Zimmermann; K Weigand
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

  10 in total
  5 in total

1.  Noninvasive determination of liver collagen content in chronic hepatitis. Multivariate regression modeling with blood chemical parameters as variables.

Authors:  S Takamatsu; H Nakabayashi; Y Okamoto; H Nakano
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

2.  Correlation between stellate cell activation and serum fibrosis markers in choline-deficient L-amino acid-defined diet-induced rat liver fibrosis.

Authors:  K Hironaka; I Sakaida; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

3.  Non-invasive investigation of liver disease in haemophilic patients.

Authors:  E J Miller; C A Lee; P Karayiannis; S J Hamilton-Dutoit; R Dick; H C Thomas; P B Kernoff
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

4.  Study of serum procollagen type III peptide in patients with hepatic cirrhosis from a clinical point of view.

Authors:  F Díaz; J Collazos; J Genollá
Journal:  Clin Investig       Date:  1993-05

5.  The Effect of Elephantopus scaber L. on Liver Regeneration after Partial Hepatectomy.

Authors:  Chin-Chuan Tsai; Jia-Ping Wu; Yueh-Min Lin; Yu-Lan Yeh; Tsung-Jung Ho; Chia-Hua Kuo; Bor-Show Tzang; Fuu-Jen Tsai; Chang-Hai Tsai; Chih-Yang Huang
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-10       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.